ALTx Therapeutics

ALTx Therapeutics is a biotechnology company specializing in the development of novel oncology treatments that target the Alternative Lengthening of Telomeres (ALT) pathway. Founded as a spin-out from the Children’s Medical Research Institute (CMRI) in Sydney, Australia, the company utilizes proprietary insights into telomere maintenance to address aggressive cancers that are resistant to conventional therapies. Their lead programs focus on small molecule inhibitors of proteins like FANCM, which are essential for the survival of ALT-positive cancer cells found in approximately 10-15% of all human tumors. By selectively targeting this mechanism, ALTx aims to provide precision medicine solutions for high-unmet-need indications such as glioblastoma and various sarcomas. The company is backed by leading life science investors and maintains a strong collaborative link with academic pioneers in telomere biology.